TJAB Forms Drug Development JV With Antisense of Australia  
7/20/2012 10:06:57 AM

by Richard Daverman, PhD

July 19, 2012 -- Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Therapeutics of Australia to develop a drug discovered by ANP. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma. TJAB will be responsible for marketing in China and Hong Kong, while ANP will retain those duties for the rest of the world. More details....

Stock Symbol: (ASX: ANP)